Back to Browse Journals » Lung Cancer: Targets and Therapy » Volume 1 » Default

Maintenance therapy for metastatic non-small-cell lung cancer – the role of pemetrexed

Authors Youval Katz, Robert A Somer

Published Date April 2010 Volume 2010:1(Default) Pages 1—7

DOI http://dx.doi.org/10.2147/LCTT.S7105

Published 12 April 2010

Youval Katz, Robert A Somer

Cooper University Hospital, Cooper Cancer Institute, University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School, Camden, New Jersey, USA

Abstract: Over the last several years, we have greatly enhanced our understanding of tumor biology and have now integrated novel and molecular-targeted therapies into front-line treatment for locally advanced and metastatic non-small-cell lung cancer (NSCLC). Despite all the recent advances, the improvement in survival outcomes for these patients has been measured in weeks compared to historical controls. Clinical researchers continue to search for the silver bullet that will allow oncologists to treat lung cancer as a chronic illness and prolong life well beyond the statistical barrier of 1 year for these patients. In that vein, maintenance therapy is emerging as a new treatment option in the metastatic setting. However, there is much controversy over the validity and cost-effectiveness of this modality. Recently, a phase III trial of pemetrexed maintenance versus best supportive care in the setting of metastatic NSCLC following non-progression after 4 cycles of platinum-based doublet therapy showed significant survival outcomes of the treatment group. This article will review the current available treatment options in metastatic NSCLC, including maintenance regimens, with particular  attention paid to the recent pemetrexed study.
Keywords: non-small-cell lung cancer, pemetrexed, maintenance therapy

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Targeted inhibition in tumors with ALK dependency

Kwak EL, Clark JW, Shaw AT

Lung Cancer: Targets and Therapy 2013, 4:1-8

Published Date: 10 January 2013

Treatment of hemophilia: a review of current advances and ongoing issues

Antonio Coppola, Mirko Di Capua, Matteo Nicola Dario, et al.

Journal of Blood Medicine 2010, 1:183-195

Published Date: 30 August 2010

The role of maintenance pemetrexed in the treatment of non-small-cell lung cancer

Saeed Rafii, Michael H Cullen

Lung Cancer: Targets and Therapy 2010, 1:101-106

Published Date: 30 July 2010

Drug resistance in lung cancer

Manish Shanker, David Willcutts, Jack A Roth, et al

Lung Cancer: Targets and Therapy 2010, 1:23-36

Published Date: 13 May 2010

Problems and barriers of pain management in the emergency department: Are we ever going to get better?

Sergey M Motov, Abu NGA Khan

Journal of Pain Research 2009, 2:5-11

Published Date: 9 December 2008

Local anesthetic failure associated with inflammation: verification of the acidosis mechanism and the hypothetic participation of inflammatory peroxynitrite

Takahiro Ueno, Hironori Tsuchiya, Maki Mizogami, Ko Takakura

Journal of Inflammation Research 2008, 1:41-48

Published Date: 13 November 2008

Applications of gold nanoparticles in cancer nanotechnology

Weibo Cai, Ting Gao, Hao Hong, Jiangtao Sun

Nanotechnology, Science and Applications 2008, 1:17-32

Published Date: 19 September 2008